Ask cannabis consumers why they use the plant and the number one answer, across every survey and demographic, is sleep. The National Institutes of Health estimates that 70 million Americans suffer from chronic sleep disorders. The global sleep aid market is worth $80 billion. And an increasing share of insomnia sufferers are reaching for cannabis instead of — or in addition to — prescription and over-the-counter sleep medications.
The industry has responded with a flood of sleep-targeted products, many of them leaning heavily on CBN, a minor cannabinoid that has been marketed as a powerful sedative. Dispensary shelves are lined with CBN gummies, CBN tinctures, and CBN capsules, all promising deep, restful sleep.
The clinical reality is more complicated — and more interesting — than the marketing suggests.
The Most Common Reason People Use Cannabis
A 2024 survey by the International Cannabis Research Society found that 74% of medical cannabis patients and 52% of recreational consumers cited improved sleep as a primary reason for use. These figures have been remarkably consistent across studies, populations, and geographies for over a decade.
The subjective reports are not in dispute. Most cannabis users report that it helps them fall asleep faster and improves their perceived sleep quality. The question the clinical research is grappling with is whether these subjective reports reflect genuine improvements in sleep architecture — the structure of sleep stages that determines how restorative sleep actually is — or whether cannabis is masking sleep problems while potentially making the underlying physiology worse.
THC and Sleep Architecture
THC’s effects on sleep are dose-dependent, bidirectional, and change with chronic use. This complexity is why blanket statements about cannabis and sleep — in either direction — are almost always misleading.
At low doses (2.5 to 5 mg of THC), the evidence supports modest sleep benefits. A 2023 randomized, double-blind, placebo-controlled trial published in the Journal of Clinical Sleep Medicine found that 5 mg of THC reduced sleep onset latency (the time it takes to fall asleep) by an average of 15 minutes compared to placebo, with minimal next-day impairment.
At moderate to high doses (15 mg and above), THC reduces REM sleep — the stage associated with dreaming, memory consolidation, and emotional processing. This is why many cannabis users report not dreaming or dreaming less — a topic explored further in our article on cannabis and dreams. While reduced REM sleep makes for subjectively “deeper” sleep, chronic REM suppression has been linked to impaired cognitive function, mood disturbances, and reduced emotional resilience in long-term studies of other REM-suppressing substances.
A 2024 polysomnography study from the University of Western Ontario tracked sleep architecture in 34 daily cannabis users and 34 non-using controls over a two-week period. The cannabis users showed significantly less REM sleep (16.4% vs. 22.1% of total sleep time) and more time in NREM Stage 2, a lighter sleep stage. Total sleep time was similar between groups, but the architecture was meaningfully different.
The tolerance question adds another layer. Regular users develop tolerance to THC’s sleep-inducing effects within days to weeks, often requiring escalating doses to achieve the same sleep onset benefits. Discontinuation after regular use produces a well-documented rebound insomnia effect — a temporary worsening of sleep that drives many users back to cannabis, creating a cycle that resembles dependence even when the underlying mechanism is primarily physiological rather than addictive.
The CBN Marketing Machine vs. the Clinical Evidence
CBN, or cannabinol, has become the cannabis industry’s designated sleep cannabinoid. Products marketed as sleep aids prominently feature CBN, often with implied or explicit claims of sedative potency. Some brands have described CBN as “the most powerful sedative in the plant world.”
The evidence does not support these claims.
A comprehensive review published in the Journal of Cannabis Research in 2024 identified exactly one human study on CBN and sleep — a 1975 trial with five participants that found CBN enhanced the sedative effects of THC but had no significant sedative effect on its own. Every subsequent citation of CBN as a sleep aid traces back to this single, small, 50-year-old study.
More recent preclinical work has failed to establish a clear sedative mechanism for CBN. A 2023 study at the University of Sydney tested CBN at a range of doses in rodent sleep models and found no significant effect on sleep onset, total sleep time, or sleep architecture. The authors concluded that CBN’s reputation as a sedative “appears to be based more on anecdotal report and commercial interest than on pharmacological evidence.”
What CBN may actually be doing in commercial sleep products is serving as a marker for aged cannabis. CBN is a degradation product of THC — it forms as THC breaks down over time. Historically, aged cannabis with higher CBN content was associated with more sedating effects, but this may reflect the presence of other degradation compounds and terpenes rather than CBN specifically.
The responsible conclusion, based on available evidence, is that CBN’s role in sleep is unproven. Consumers spending premium prices on CBN-specific products may be paying for a placebo effect and effective marketing rather than a pharmacologically validated sleep aid.
CBD for Sleep
CBD’s relationship with sleep is better studied than CBN’s, though the picture remains nuanced. Unlike THC, CBD does not directly induce sleep at typical doses. Instead, the evidence suggests it may improve sleep indirectly through its anxiolytic (anti-anxiety) effects.
A 2019 case series published in The Permanente Journal followed 72 adults with anxiety and poor sleep who were treated with CBD. After one month, 66.7% reported improved sleep scores, though 25% experienced worsened sleep, and the improvements fluctuated over the three-month follow-up period.
A more rigorous 2025 randomized controlled trial from the University of Queensland tested 300 mg of CBD daily in patients with diagnosed insomnia. The results showed a statistically significant improvement in subjective sleep quality and a modest reduction in wake-after-sleep-onset (the amount of time spent awake during the night) compared to placebo. Importantly, CBD did not suppress REM sleep or produce tolerance effects over the eight-week study period.
The emerging consensus is that CBD may benefit sleep most when poor sleep is driven by anxiety, pain, or hyperarousal rather than primary insomnia. This aligns with CBD’s known pharmacological profile as an anxiolytic and anti-inflammatory compound rather than a direct sedative.
Cannabis vs. Conventional Sleep Medications
The comparison that consumers are implicitly making when they choose cannabis over a prescription sleep aid deserves a more rigorous treatment than it typically receives.
Benzodiazepines and Z-drugs (zolpidem, zaleplon) are effective at inducing sleep but carry well-documented risks: tolerance development, rebound insomnia, cognitive impairment, fall risk in elderly patients, and physiological dependence. Long-term use has been associated with increased risk of dementia in observational studies, though causality remains debated.
Cannabis carries its own risk profile: REM suppression, tolerance development, potential for cannabis use disorder (estimated at 9% of users by NIH data), withdrawal-related sleep disruption, and in some individuals, paradoxical anxiety or racing thoughts that worsen sleep.
Neither option is risk-free. The honest assessment is that cannabis may be a reasonable sleep aid for some people — particularly those whose insomnia is related to anxiety or chronic pain — while being a poor choice for others, particularly those who need healthy REM sleep for cognitive performance or who are prone to escalating use patterns.
Practical Guidance from the Research
The clinical evidence, taken as a whole, supports several actionable conclusions for consumers using cannabis for sleep.
Lower THC doses appear to produce better sleep outcomes with fewer side effects than higher doses. For a comprehensive breakdown of how to use cannabis for sleep, including dosing protocols and product recommendations, see our complete cannabis sleep guide. The dose-response curve for THC and sleep is not linear — more is not better, and the 5 to 10 mg range shows the most favorable risk-benefit profile in controlled studies.
CBD may be a useful adjunct or alternative for sleep problems rooted in anxiety. Doses in the 25 to 300 mg range have shown benefit in various studies, though individual response varies considerably.
CBN-specific products lack clinical support for their sleep marketing claims. Consumers should approach these products with appropriate skepticism and consider whether a full-spectrum product might provide more value.
Tolerance management matters. Taking regular breaks from cannabis use (even 48 to 72 hours) can help reset tolerance and maintain sleep benefits, while reducing the risk of dependence and withdrawal-related insomnia.
The industry has a responsibility to market sleep products honestly — which means stopping the CBN hype train until the clinical evidence catches up with the claims. Consumers deserve better than a 50-year-old study and a marketing budget.
This article is for informational purposes only and does not constitute medical advice. Consult a healthcare provider before using cannabis for sleep or modifying any sleep treatment regimen.